Official media partner of business and marketing eventsEvents calendar
VANTAGE52

Loading market data

Markets

Blackstone Will Cover Up to $1.5 Billion of Costs for Pfizer’s Monthly Obesity Drug

The money for berobenatide runs through 2028 and caps what Blackstone pays towards trials. Blackstone earns milestone payments only if US regulators approve monthly dosing and sales targets are met, and it takes no stake in the drug.

Collage at night with the Pfizer headquarters and its lit logo, a Blackstone office tower, a scientist holding a vial, an injection pen, a tape measure, stacks of banknotes and blue torn paper strips.
Illustration by VANTAGE52
VANTAGE52 Editorial · Edited by VANTAGE52 Editorial · Updated

Funds managed by Blackstone Life Sciences will pay up to $1.5 billion of the development costs of berobenatide, Pfizer’s experimental once-a-month obesity injection, through 2028, the two companies announced on 11 November after the close of US trading.

The headline figure is a ceiling on cost-sharing, not a payment to Pfizer for an asset. Blackstone covers trial costs up to that amount. In return it becomes eligible for milestone payments, but only if US regulators approve monthly dosing of injectable berobenatide on its own for chronic weight management and the drug then reaches certain sales milestones.

Blackstone gets no rights or ownership in the drug, and Pfizer keeps full control of the programme. That structure turns part of Pfizer’s obesity spending into a contingent obligation. If berobenatide fails, Blackstone has absorbed some of the cost. If it succeeds, Pfizer pays Blackstone out of the drug’s commercial success, on terms neither company has disclosed.

A Ceiling on Costs, Not a Purchase Price

Pfizer’s release sets out the essentials. The money comes from funds managed by Blackstone Life Sciences, which has $18 billion of assets under management, with Blackstone’s perpetual private equity strategy, known as BXPE, investing alongside. Any milestone payments, if earned, are payable over several years. The release describes milestone payments only. It does not mention royalties, and it does not say how large the milestones could be.

Pfizer has not said how it will account for the deal, but its filings show how it booked an earlier Blackstone arrangement. The funding was recognised as a reduction of research and development expense over the period of the related costs, because the contract transfers substantive risk to the financial partner. The present value of any milestones owed was to be recorded as an intangible asset and amortised, with interest accruing on the liability to Blackstone.

Pfizer’s Third Funding Deal With Blackstone

Pfizer has used the model before. In April 2023 it agreed with Blackstone to receive up to $550 million between 2023 and 2026 to co-fund development of specified treatments. In March 2025 it signed a second arrangement for up to $326 million between 2025 and 2028. Under that one, Blackstone can receive approval milestones of up to $277 million, paid over one to three years, and sales milestones of up to $897 million, paid over five to seven years. Pfizer’s filings do not name the treatments involved.

On those disclosed maximums, the 2025 deal could return up to about $1.17 billion for up to $326 million of funding, although the sales milestones depend on cumulative sales thresholds and the payments are spread over years. Berobenatide’s terms have not been disclosed and may differ. The new agreement is almost three times the size of the 2023 one.

Nicholas Galakatos, global head of Blackstone Life Sciences, said the firm was “pleased to further expand our relationship with Pfizer” and called berobenatide “the anchor of Pfizer’s cardiometabolic pipeline.” Cecile Guegan, whose appointment as Pfizer’s chief financial officer took effect on 1 November after she had served as interim finance chief since 16 August, presented it as a capital decision that helps Pfizer keep “the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas.”

A Wager on Monthly Dosing

Berobenatide, previously called MET-097i, came to Pfizer with Metsera, the obesity biotech it bought in November 2025 for $65.60 a share in cash, an enterprise value of about $7.0 billion, plus a contingent value right worth up to $20.65 a share tied to three clinical and regulatory milestones. Pfizer said at the time that the acquisition would dilute earnings through 2030.

Pfizer describes berobenatide as a potential first-in-class monthly GLP-1 receptor agonist. The leading obesity injections, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, are taken weekly, so the monthly schedule is the feature Pfizer is relying on to set its drug apart.

The evidence so far is mid-stage. In the VESPER-3 trial, presented at the American Diabetes Association’s meeting on 6 June, patients moved from weekly to monthly injections lost up to 12.3% more weight than those on placebo after 28 weeks at the 4.8 mg monthly dose. The study’s final endpoint is at 64 weeks. Pfizer plans more than 20 obesity trials this year, including 10 ongoing and planned Phase 3 studies of berobenatide in weight management and in conditions such as knee osteoarthritis and obstructive sleep apnoea.

That breadth matters for Blackstone because the payments described in the release depend on one outcome, US approval of monthly berobenatide as a stand-alone treatment for chronic weight management. The release does not say whether other approvals, such as weekly dosing, combinations with amylin drugs or the comorbidity indications, carry payments of their own. Zacks Equity Research reported that Pfizer is targeting the first of a series of potential approvals in 2028, the year the funding window closes.

Private Capital Moves Into Late-Stage Trials

Blackstone has written similar cheques elsewhere. In March 2024 it agreed to provide Moderna with up to $750 million for its influenza vaccine programme in exchange for commercial milestones and royalties in the low single digits, BioSpace reported, and Moderna said it would record the money as a reduction in research spending. In March 2026 it committed $400 million over four years to duvakitug, the late-stage gut disease drug Teva is developing with Sanofi, with a milestone payment due on US approval followed by further payments and royalties on sales, BioPharma Dive reported.

The Pfizer agreement is the largest of the three by headline ceiling, and the only one whose announcement mentions no royalty. For a drugmaker the appeal is money that arrives without issuing shares or taking on conventional debt, in a year when long-term borrowing costs have climbed, with the 10-year US Treasury yield nearing 5% in September. The cost is that the most successful programmes end up with the most expensive financing, because the milestones are paid only when the drug works.

Rivals are financing their next generation of cardiometabolic drugs in their own ways. Novo Nordisk, for one, agreed in September a discovery and licensing pact worth up to $1.4 billion with Orbis Medicines aimed at turning injectable therapies into pills.

The Readouts That Will Set Blackstone’s Return

The next markers are clinical. The 64-week results from VESPER-3 will show whether monthly maintenance holds weight loss over a longer period. The Phase 3 programme, including VESPER-6, the study of monthly dosing that is now enrolling, will decide whether US regulators receive the application Blackstone needs.

Until then, the $1.5 billion is a cap on what Blackstone will pay as the trials run. Whether it proves cheap or expensive money for Pfizer depends on a single regulatory decision that, on the timetable Zacks reported, is not expected before 2028.

Tags

Key Concepts

Share this story

Sources

Where the reporting above comes from. Follow these to check the figures and statements for yourself.

More From Markets

Choose which cookies we may use. You can change this at any time from “Manage cookies” at the foot of every page.